199 related articles for article (PubMed ID: 30350209)
1. Minimal Residual Disease Quantification in Chronic Lymphocytic Leukemia: Clinical Significance and Flow Cytometric Methods.
Böttcher S
Methods Mol Biol; 2019; 1881():211-238. PubMed ID: 30350209
[TBL] [Abstract][Full Text] [Related]
2. Flow Cytometric MRD Detection in Selected Mature B-Cell Malignancies.
Böttcher S
Methods Mol Biol; 2019; 1956():157-197. PubMed ID: 30779035
[TBL] [Abstract][Full Text] [Related]
3. Optimization and Validation of an 8-Color Single-Tube Assay for the Sensitive Detection of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia Detected via Flow Cytometry.
Dowling AK; Liptrot SD; O'Brien D; Vandenberghe E
Lab Med; 2016 May; 47(2):103-11. PubMed ID: 27069028
[TBL] [Abstract][Full Text] [Related]
4. Flow cytometric MRD detection in selected mature B-cell malignancies.
Böttcher S; Ritgen M; Kneba M
Methods Mol Biol; 2013; 971():149-74. PubMed ID: 23296963
[TBL] [Abstract][Full Text] [Related]
5. Validation of a modified pre-lysis sample preparation technique for flow cytometric minimal residual disease assessment in multiple myeloma, chronic lymphocytic leukemia, and B-non Hodgkin lymphoma.
Bayly E; Nguyen V; Binek A; Piggin A; Baldwin K; Westerman D; Came N
Cytometry B Clin Cytom; 2020 Sep; 98(5):385-398. PubMed ID: 32530574
[TBL] [Abstract][Full Text] [Related]
6. Performance of eight-color dry antibody reagent in the detection of minimal residual disease in chronic lymphocytic leukemia samples.
Bento L; Correia R; de Sousa F; Vaz A; Pedro E; Schimidell D; Millan N; Passaro M; Barroso R; Bacal N
Cytometry B Clin Cytom; 2020 Nov; 98(6):529-535. PubMed ID: 32251553
[TBL] [Abstract][Full Text] [Related]
7. Minimal Residual Disease in Chronic Lymphocytic Leukemia in the Era of Novel Agents: A Review.
Thompson M; Brander D; Nabhan C; Mato A
JAMA Oncol; 2018 Mar; 4(3):394-400. PubMed ID: 28750119
[TBL] [Abstract][Full Text] [Related]
8. A look into the future: can minimal residual disease guide therapy and predict prognosis in chronic lymphocytic leukemia?
Ghia P
Hematology Am Soc Hematol Educ Program; 2012; 2012():97-104. PubMed ID: 23233566
[TBL] [Abstract][Full Text] [Related]
9. Detecting minimal residual disease in patients with chronic lymphocytic leukemia using 8-color flow cytometry protocol in routine hematological practice.
Stehlíková O; Chovancová J; Tichý B; Krejčí M; Brychtová Y; Panovská A; Francová Skuhrová H; Burčková K; Borský M; Loja T; Mayer J; Pospíšilová S; Doubek M
Int J Lab Hematol; 2014 Apr; 36(2):165-71. PubMed ID: 24028768
[TBL] [Abstract][Full Text] [Related]
10. Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis.
Böttcher S; Stilgenbauer S; Busch R; Brüggemann M; Raff T; Pott C; Fischer K; Fingerle-Rowson G; Döhner H; Hallek M; Kneba M; Ritgen M
Leukemia; 2009 Nov; 23(11):2007-17. PubMed ID: 19641522
[TBL] [Abstract][Full Text] [Related]
11. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial.
Böttcher S; Ritgen M; Fischer K; Stilgenbauer S; Busch RM; Fingerle-Rowson G; Fink AM; Bühler A; Zenz T; Wenger MK; Mendila M; Wendtner CM; Eichhorst BF; Döhner H; Hallek MJ; Kneba M
J Clin Oncol; 2012 Mar; 30(9):980-8. PubMed ID: 22331940
[TBL] [Abstract][Full Text] [Related]
12. Performance of a novel eight-color flow cytometry panel for measurable residual disease assessment of chronic lymphocytic leukemia.
Chen X; Chen X; Zhao S; Shi Y; Zhang N; Guo Z; Qiao C; Jin H; Zhu L; Zhu H; Li J; Wu Y
Cytometry B Clin Cytom; 2024 May; 106(3):181-191. PubMed ID: 38535092
[TBL] [Abstract][Full Text] [Related]
13. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.
Rawstron AC; Fazi C; Agathangelidis A; Villamor N; Letestu R; Nomdedeu J; Palacio C; Stehlikova O; Kreuzer KA; Liptrot S; O'Brien D; de Tute RM; Marinov I; Hauwel M; Spacek M; Dobber J; Kater AP; Gambell P; Soosapilla A; Lozanski G; Brachtl G; Lin K; Boysen J; Hanson C; Jorgensen JL; Stetler-Stevenson M; Yuan C; Broome HE; Rassenti L; Craig F; Delgado J; Moreno C; Bosch F; Egle A; Doubek M; Pospisilova S; Mulligan S; Westerman D; Sanders CM; Emerson R; Robins HS; Kirsch I; Shanafelt T; Pettitt A; Kipps TJ; Wierda WG; Cymbalista F; Hallek M; Hillmen P; Montserrat E; Ghia P
Leukemia; 2016 Apr; 30(4):929-36. PubMed ID: 26639181
[TBL] [Abstract][Full Text] [Related]
14. Novel flow-cytometric analysis based on BCD5+ subpopulations for the evaluation of minimal residual disease in chronic lymphocytic leukaemia.
Maloum K; Sutton L; Baudet S; Laurent C; Bonnemye P; Magnac C; Merle-Béral H
Br J Haematol; 2002 Dec; 119(4):970-5. PubMed ID: 12472575
[TBL] [Abstract][Full Text] [Related]
15. Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation.
Sánchez ML; Almeida J; Vidriales B; López-Berges MC; García-Marcos MA; Moro MJ; Corrales A; Calmuntia MJ; San Miguel JF; Orfao A
Leukemia; 2002 Aug; 16(8):1460-9. PubMed ID: 12145686
[TBL] [Abstract][Full Text] [Related]
16. Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group.
Kovacs G; Robrecht S; Fink AM; Bahlo J; Cramer P; von Tresckow J; Maurer C; Langerbeins P; Fingerle-Rowson G; Ritgen M; Kneba M; Döhner H; Stilgenbauer S; Klapper W; Wendtner CM; Fischer K; Hallek M; Eichhorst B; Böttcher S
J Clin Oncol; 2016 Nov; 34(31):3758-3765. PubMed ID: 27573660
[TBL] [Abstract][Full Text] [Related]
17. Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ-PCR.
Raponi S; Della Starza I; De Propris MS; Del Giudice I; Mauro FR; Marinelli M; Di Maio V; Piciocchi A; Foà R; Guarini A
Br J Haematol; 2014 Aug; 166(3):360-8. PubMed ID: 24735016
[TBL] [Abstract][Full Text] [Related]
18. Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL.
Rawstron AC; Böttcher S; Letestu R; Villamor N; Fazi C; Kartsios H; de Tute RM; Shingles J; Ritgen M; Moreno C; Lin K; Pettitt AR; Kneba M; Montserrat E; Cymbalista F; Hallek M; Hillmen P; Ghia P;
Leukemia; 2013 Jan; 27(1):142-9. PubMed ID: 23041722
[TBL] [Abstract][Full Text] [Related]
19. Monitoring of minimal residual disease in acute leukemia by multiparametric flow cytometry.
Kusenda J; Fajtova M; Kovarikova A
Neoplasma; 2014; 61(2):119-27. PubMed ID: 24299307
[TBL] [Abstract][Full Text] [Related]
20. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.
Flores-Montero J; Sanoja-Flores L; Paiva B; Puig N; García-Sánchez O; Böttcher S; van der Velden VHJ; Pérez-Morán JJ; Vidriales MB; García-Sanz R; Jimenez C; González M; Martínez-López J; Corral-Mateos A; Grigore GE; Fluxá R; Pontes R; Caetano J; Sedek L; Del Cañizo MC; Bladé J; Lahuerta JJ; Aguilar C; Bárez A; García-Mateo A; Labrador J; Leoz P; Aguilera-Sanz C; San-Miguel J; Mateos MV; Durie B; van Dongen JJM; Orfao A
Leukemia; 2017 Oct; 31(10):2094-2103. PubMed ID: 28104919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
